Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Has Average Target Price of $62.40 According to Analysts

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been given an average rating of “Hold” by the six research firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price target among analysts that have covered the stock in the last year is $62.40.

A number of brokerages recently weighed in on SUPN. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. Finally, Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th.

Supernus Pharmaceuticals Stock Down 1.5%

Shares of Supernus Pharmaceuticals stock opened at $39.57 on Tuesday. Supernus Pharmaceuticals has a 52 week low of $39.36 and a 52 week high of $59.68. The company has a market capitalization of $2.30 billion, a PE ratio of -20.61, a price-to-earnings-growth ratio of 0.74 and a beta of 0.55. The stock’s fifty day moving average is $43.95 and its two-hundred day moving average is $46.46.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). The company had revenue of $219.06 million for the quarter, compared to analysts’ expectations of $205.31 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm’s revenue for the quarter was up 32.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.40 earnings per share. As a group, research analysts anticipate that Supernus Pharmaceuticals will post 1.97 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio purchased a new position in Supernus Pharmaceuticals during the 2nd quarter valued at about $25,000. Rockefeller Capital Management L.P. lifted its position in shares of Supernus Pharmaceuticals by 354.8% in the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company’s stock worth $42,000 after purchasing an additional 660 shares during the period. Global Retirement Partners LLC bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $64,000. Versant Capital Management Inc boosted its stake in shares of Supernus Pharmaceuticals by 47.2% during the third quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company’s stock valued at $65,000 after purchasing an additional 482 shares in the last quarter. Finally, Nykredit A S bought a new position in shares of Supernus Pharmaceuticals during the second quarter valued at approximately $110,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for diseases of the central nervous system (CNS). The company’s portfolio has primarily addressed epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on differentiated formulations and products designed to improve treatment convenience and patient outcomes.

Supernus markets Oxtellar XR (oxcarbazepine extended-release) for the treatment of partial-onset seizures and Trokendi XR (topiramate extended-release) for certain seizure disorders and the prevention of migraine headaches.